Compare TNGX & PFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TNGX | PFL |
|---|---|---|
| Founded | 2014 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 374.5M |
| IPO Year | N/A | N/A |
| Metric | TNGX | PFL |
|---|---|---|
| Price | $8.63 | $8.37 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $12.50 | N/A |
| AVG Volume (30 Days) | ★ 2.8M | 113.7K |
| Earning Date | 11-04-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.53% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $66,501,000.00 | N/A |
| Revenue This Year | $53.01 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 53.29 | N/A |
| 52 Week Low | $1.03 | $6.98 |
| 52 Week High | $11.20 | $8.62 |
| Indicator | TNGX | PFL |
|---|---|---|
| Relative Strength Index (RSI) | 43.31 | 43.45 |
| Support Level | $8.42 | $8.33 |
| Resistance Level | $8.98 | $8.42 |
| Average True Range (ATR) | 0.57 | 0.04 |
| MACD | -0.16 | -0.01 |
| Stochastic Oscillator | 10.25 | 16.67 |
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
PIMCO Income Strategy Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek high current income, consistent with the preservation of capital. It seeks to achieve its objectives by investing in a diversified portfolio of floating and fixed-rate debt instruments.